Apexigen Valuation
| APGNWDelisted Stock | USD 0.02 0.0001 0.66% |
Apexigen seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Apexigen from analyzing the firm fundamentals such as number of shares shorted of 2.41 K, and Net Income of (32.07 M) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Apexigen's price fluctuation is somewhat reliable at this time. Calculation of the real value of Apexigen is based on 3 months time horizon. Increasing Apexigen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Apexigen stock is determined by what a typical buyer is willing to pay for full or partial control of Apexigen. Since Apexigen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Apexigen Stock. However, Apexigen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0153 | Real 0.0145 | Hype 0.02 | Naive 0.0131 |
The intrinsic value of Apexigen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Apexigen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Apexigen helps investors to forecast how Apexigen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Apexigen more accurately as focusing exclusively on Apexigen's fundamentals will not take into account other important factors: Apexigen Total Value Analysis
Apexigen is presently estimated to have takeover price of 0 with market capitalization of 0, debt of 106 K, and cash on hands of 21.62 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Apexigen fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 0 | 106 K | 21.62 M |
Apexigen Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Apexigen indicates not a very effective usage of assets in November.Apexigen Profitability Analysis
Net Loss for the year was (32.07 M) with profit before overhead, payroll, taxes, and interest of 0.About Apexigen Valuation
Our relative valuation model uses a comparative analysis of Apexigen. We calculate exposure to Apexigen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Apexigen's related companies.Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. The company was founded in 2010 and is based in San Carlos, California. Apexigen Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 27 people.
Apexigen Growth Indicators
Investing in growth stocks can be very risky. If the company such as Apexigen does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 19.8 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Apexigen Stock
If you are still planning to invest in Apexigen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Apexigen's history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |